Printer Friendly

GENECOR INTERNATIONAL ANNOUNCES NEW PRESIDENT AND CEO

 GENECOR INTERNATIONAL ANNOUNCES NEW PRESIDENT AND CEO
 ROCHESTER, N.Y., Feb. 5 /PRNewswire/ -- Genecor International, Inc.


announced the appointment of a new President and CEO, W. Thomas Mitchell. Mitchell assumed his new responsibilities at the beginning of this year, working at the company headquarters in Rochester.
 Mitchell has been with Genecor International (GCI) since its inception. His most recent position was executive vice president responsible for company operations. Mitchell was a key player in the development of a commercial biotechnology group at Eastman Kodak starting in 1984. He began his career at Kodak in 1969 following graduation from Drexel University with a B.Sc. degree in chemical engineering.
 Robert E. Leach, the former president and CEO of Genecor International, remains as an employee in an advisory capacity through April 30, 1992. At that time, he will pursue other interests.
 Genecor International is a diversified multinational industrial biotechnology company. Its products encompass a range of fine and specialty biochemicals including a number of industrial enzymes. GCI was the first company in the world to produce tankerload quantities of an enzyme produced using recombinant DNA technology. GCI's enzymes are used in various industries including detergents, starch processing, textiles, food and feed processing, and paper and pulp preparation. Genecor is a joint venture of Eastman Kodak Company (NYSE: EK), (Rochester, N.Y.) and Cultor Ltd. (Helsinki, Finland).
 -0- 2/5/92
 /CONTACT: Edward R. Robinson of Genecor International, Inc., 716-256-5210/ CO: Genecor International, Inc.; Eastman Kodak Company ST: New York IN: CHM SU: PER


LC -- CL004 -- 7183 02/05/92 12:21 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 5, 1992
Words:260
Previous Article:UNIMED TO REGAIN CANADIAN MARKETING RIGHTS FOR MARINOL
Next Article:WETTERAU FINANCE CO. CALLS FOR REDEMPTION OF ITS 9 PERCENT SUBORDINATED NOTES ON MARCH 6, 1992
Topics:


Related Articles
IMPROVED SNOWMAKING TECHNOLOGY FOR XVI OLYMPICS
PHYTOPHARMACEUTICALS INC. NAMES DR. MAX WILHELM TO SCIENTIFIC ADVISORY BOARD
PHYTOPHARMACEUTICALS INC. NAMES DR. MAX WILHELM TO SCIENTIFIC ADVISORY BOARD
Partners Announce Breakthrough in Production of Chemicals Via Biotechnology
2005 Antibody World Summit Attracting Hundreds of Top Executives, Business Development, and Researchers from Around the World for July 25-27...
Genencor International, Inc. to Present at the Merrill Lynch Pharmaceutical, Biotechnology and Medical Device Conference.
Manpower Inc. Names Stephanie A. Burns to Board of Directors.
IBC's Inaugural Protein Engineering Event to Take Place Alongside Flagship Antibody Engineering Event.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters